[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anthracycline-induced-cardiac-toxicity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anthracycline-induced-cardiac-toxicity":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100612487","phase-4-rosuvastatin-for-prevention-of-anthracycline-induced-cardiac-dysfunction-in-breast-cancer-patients-100612487",false,"NCT07254221","Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients","Evaluation of Rosuvastatin Efficacy in Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients After Chemotherapy","ROSUBREAST","Inclusion Criteria:\n\n* Female individuals with ≥18 years of age\n* Documented breast cancer diagnosis based on imaging and pathology findings\n* Scheduled to receive the first time anthracycline-based chemotherapy\n\nExclusion Criteria:\n\n* Baseline LVEF \\\u003C 50%\n* Prior Statin use or Statin use is indicated based on guidelines\n* history of congestive heart failure (CHF) or cardiomyopathy\n* Pregnancy or breastfeeding\n* Unable to provide informed consent\n* Unexplained persistent elevation of transaminases (\\>3 times upper limits of normal)\n* Concomitant use of oral cyclosporine\n* Metastatic invasion of cancer to other organs\n* Previous cycles of chemotherapy\n* Any contraindication for statin use","FEMALE","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study, called \"ROSUBREAST\", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based chemotherapy. A total of 400 participants will be randomly assigned to receive either rosuvastatin or placebo for 12 months. The main goal is to determine whether rosuvastatin can prevent cancer treatment-related cardiac dysfunction (CTRCD), defined as a significant drop in heart pumping function. The study will also assess changes in cardiac strain, blood biomarkers, symptoms of heart failure, quality of life, and possible side effects.",[27,28,29,30],"Anthracycline-induced Cardiac Toxicity","Breast Cancer","Anthracycline Related Cardiotoxicity in Breast Cancer","Anthracycline-induced Cardiotoxicity",[32,33,34,35,36,37,38,39,40],"Breast cancer","rosuvastatin","statin therapy,","cancer-related treatment cardiac dysfunction","anthracycline induced cardiomyopathy","cardiac dysfunction","cardiotoxicity","chemotherapy","anthracycline","NOT_YET_RECRUITING","2025-12-03",{"date":44,"type":45},"2025-12-10","ACTUAL",{"date":47,"type":21},"2026-02-01",{"date":49,"type":21},"2028-04-21",{"name":51,"class":52},"Shiraz University of Medical Sciences","OTHER",7,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100611783","phase-2-use-of-dapagliflozin-in-primary-prevention-of-cardiotoxicity-of-anthracycline-chemotherapy-in-breast-cancer-patients-100611783","NCT07245069","Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients","Alpaca","Inclusion Criteria:\n\n* Adults ≥18 years.\n* Histologically confirmed breast cancer with planned (neo)adjuvant anthracycline-based chemotherapy (4 cycles of epirubicin + cyclophosphamide or doxorubicin + cyclophosphamide).\n* Eligible to start dapagliflozin or placebo prior to or at initiation of chemotherapy.\n* Able to perform baseline echocardiography, vascular ultrasound (FMD and carotid stiffness), 6-minute walk test, and biomarker sampling.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Known heart failure (any prior diagnosis of HF).\n* Clinically significant valvular heart disease.\n* Prior exposure to chemotherapy or radiotherapy to the left chest.\n* Type 1 diabetes mellitus.\n* Symptomatic hypotension.\n* History of recurrent urinary tract infections.\n* History of diabetic ketoacidosis or ketonemia.\n* Severe hepatic impairment (ALT, AST, ALP \\>3× upper limit of normal).\n* Severe renal impairment (eGFR \\\u003C20 mL\u002Fmin\u002F1.73 m²).\n* Known allergy or intolerance to SGLT-2 inhibitors.\n* Any use of SGLT-2 inhibitor therapy within 3 months prior to enrollment.\n* Pregnancy or breastfeeding.\n* Any condition that, in the investigator's judgment, could interfere with study participation, safety, or completion.","ALL",{"count":63,"type":21},100,[65],"PHASE2","The goal of this randomized, double-blind, placebo-controlled clinical trial is to determine whether dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, can help prevent anthracycline-induced cardiotoxicity caused by anthracycline chemotherapy in adult women with breast cancer receiving (neo)adjuvant treatment.\n\nThe main questions the study aims to answer are:\n\ni) Does dapagliflozin reduce the decline in left ventricular function (measured by LVEF, GLS, and myocardial work) during and after anthracycline therapy? ii) Does dapagliflozin lessen the deteriorating effect of chemotherapy on endothelial function and arterial stiffness? iii) Does dapagliflozin effect levels of cardiac injury and inflammation biomarkers (e.g., hs-troponin T, NT-proBNP, ST-2, GDF-15, galectin-3, IL-6, MPO)?\n\nResearchers will compare dapagliflozin 10 mg daily with placebo to see whether those receiving dapagliflozin experience less heart and vascular impairment during treatment.\n\nParticipants will:\n\n* Take either dapagliflozin or placebo once daily during anthracycline chemotherapy.\n* Undergo heart and vascular ultrasound, and a 6-minute walk test before chemotherapy and again at 24 and 52 weeks.\n* Provide blood samples before, during and after chemotherapy to measure cardiac biomarkers.\n* Complete multiple questionnaires on quality of life.",[68,27,69,70,28],"Heart Failure","Endothelial Function (FMD)","Arterial Stiffness",[72,73,28,74,75,76,77,78,79,80,81,82,68,83,84],"Anthracycline-induced cardiac toxicity","Dapagliflozin","Cardio-Oncology","Primary Prevention","Global Longitudinal Strain","Myocardial Work","Endothelial Function","Flow-Mediated Dilation","Pulse Wave Velocity","Troponin","NT-proBNP","Inflammation","Sodium-Glucose Transporter 2 Inhibitors","RECRUITING","2025-11-17",{"date":88,"type":45},"2025-11-24",{"date":90,"type":45},"2025-02-01",{"date":92,"type":21},"2029-02",{"name":94,"class":52},"University Medical Centre Ljubljana",1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":61,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100456424","remote-ischemic-conditioning-in-lymphoma-patients-receiving-anthracyclines-100456424","NCT05223413","REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs","RESILIENCE","Inclusion Criteria:\n\n≥18 years old NHL, HL or breast cancer diagnosis Scheduled to undergo chemotherapy including ≥ 240 mg\u002Fk2 cumulative dose of anthracyclines.\n\nPre-chemo LVEF \\>40% on screening echocardiography.\n\nPresence of ≥1 of the following risk factors for developing cardiotoxicity:\n\nPrevious coronary artery disease (any of the following):\n\nPrevious coronary revascularisation (PCI or CABG) or Medical history of previous significant nonrevascularized coronary stenosis Previous Acute Coronary Syndrome \u002F Acute Myocardial Infarction with a LVEF \\> 40 LVEF 41-54% Age ≥ 65 years old Previous diagnosis of arterial hypertension (with or without treatment) Chronic kidney disease (estimated glomerular filtration rate \\\u003C60ml\u002Fmin\u002F1.73m2) Current or former smoker. Obesity (BMI≥30 kg\u002Fm2) LVH on screening echocardiography (LV thickness ≥12mm). High alcohol intake (≥21 alcoholic beverages per week) Sinus rhythm on screening ECG Previous diagnosis of diabetes (except those treated with sulfonylureas or those with neuropathy) Previous non-anthracycline-based chemotherapy Signed Informed Consent Form (ICF)\n\nExclusion Criteria:\n\n* History of any of the following diseases:\n\n  * Any cancer who received anthracyclines treatment before the index episode.\n  * Previous clinical diagnosis of heart failure.\n  * Permanent atrial fibrillation (AF).\n  * Severe valvular or sub-valvular heart disease.\n  * Severe peripheral arterial disease in the upper extremities or arteriovenous (AV) shunt in the arm selected for RIPC.\n* Clinical diagnosis of diabetes neuropathy\n* Contraindication for CMR:\n\n  * Severe claustrophobia.\n  * Any device which is known to threaten or pose hazard in all MR environments (http:\u002F\u002Fwww.mrisafety.com\u002F).\n  * Patients with implanted biomedical cardiac devices: pacemakers, ICDs or CRT.\n* Severe thrombocytopenia (platelets \\\u003C50,000\u002FµL) on any blood test within the previous 3 months.\n* Patients participating in other clinical trials.\n* Impossibility to consent or undergo study follow-ups.","99 Years",{"count":105,"type":21},608,[107],"NA","Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning (RIPC) in Lymphoma patients receiving anthracyclines.",[27,110],"Lymphoma","2025-09-12",{"date":113,"type":45},"2025-09-18",{"date":115,"type":45},"2022-01-18",{"date":117,"type":21},"2026-12",{"name":119,"class":52},"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III",24]